Identification of Candida species isolated from patients in intensive care unit and in vitro susceptibility to fluconazole for a 3-year period

Mycoses

Volumn 50, Issue 1, 2007, Pages 52-57

  Comert, Fusun ^a   Kulah, Canan ^a   Aktas, Elif ^a   Eroglu, Ozlem ^a   Ozlu, Nagihan ^a  

^a ZONGULDAK KARAELMAS UNIVERSITY   (Turkey)

Author keywords

Candida species; Fluconazole susceptibility; Turkey

Indexed keywords

FLUCONAZOLE;

ADULT; AGED; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; FUNGUS IDENTIFICATION; FUNGUS ISOLATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; TURKEY (REPUBLIC);

ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FEMALE; FLUCONAZOLE; HOSPITALS, UNIVERSITY; HUMANS; INTENSIVE CARE UNITS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; TURKEY;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 33846015821     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2006.01309.x     Document Type: Article

References (23)

1. Fridkin SK, Jarvis WR. Epidemiology of nosocomial fungal infections. Clin Microbiol Rev 1996; 9: 499-511.
2. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8.
3. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP and SCOPE Participant Group. National surveillence of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE Program. Diagn Microbiol Infect Dis 1998; 30: 121-9.
4. Arikan S, Rex JH. Antifungal agents. In: Murray PR, Pfaller MA, Baron EJ, Jongensen JH, Yolken RH (eds), Manual of Clinical Microbiology, 8th edn. Washington, DC: American Society for Microbiology, 2003: 1859-68.
5. Rex JH, Rinaldi MG, Pfaller MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995; 39:1-8.
6. Larone DH. Medical Important Fungi: A Guide to Identification. Washington, DC: American Society for Microbiology, 1993; pp. 54-75.
7. Hazen KC, Howell SA. Candida, Cryptococcus and other yeast of medical importance. In: Murray PR, Pfaller MA, Baron EJ, Jongensen JH, Yolken RH, (eds.), Manual of Clinical Microbiology, 8 th edn. Washington, DC: American Society for Microbiology, 2003: 1693-711.
8. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast; Approved Standard. NCCLS Document M27-A (ISBN 1-56238-328-0). Pennsylvania 19087: NCCLS, 940 West Valley Road, Suit 1400, Wayne, 1997.
9. SPSS for Windows release 11.01 Customer Number 114094. Turkey: Zonguldak, 2001.
10. Pfaller MA, Diekema DJ, Rinaldi MG et al. and the Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5 year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J Clin Microbiol 2005; 43: 5848-59.
11. Kucukates E, Erturan Z, Susever S, Yegenoglu Y. In vitro susceptibility of yeasts isolated from patients in intensive care units to fluconazole and amphotericin B during a 3-year period. APMIS 2005; 113: 278-83.
12. Uzun O, Arikan S, Kocagoz S, Sancak B, Unal S. Susceptibility testing of voriconazole, fluconazole, itraconazole and amphotericin B against yeast isolates in a Turkish University Hospital and effect of time of reading. Diagn Microbiol Infect Dis 2000; 38: 101-7.
13. Yapar N, Uysal U, Yucesoy M, Yuce A. Nosocomial bloodstream infections associated with Candida species in a Turkish University Hospital. Mycoses 2006; 49: 134-8.
14. Ergon MC, Yucesoy M. Evaluation of species distribution of yeasts isolated from intensive care units during the four years period. Mikrobiyol Bul 2005; 39: 309-18.
15. Zaoutis TE, Foraker E, McGowan KL et al. Antifungal susceptibility of Candida spp. isolated from pediatric patients: a survey of 4 children's hospitals. Diagn Microbiol Infect Dis 2005; 52: 295-8.
16. Faix RG. Invazive neonatal candidiasis: comparison of albicans and parapsilosis infection. Pediatr Infect Dis J 1992; 11: 88-93.
17. Pappas PG, Rex JH, Lee J et al. NIAID Mycoses Study Group. A prospective observational study of candidemia: epidemiology, therapy and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003; 37: 634-43.
18. Uzun O, Kocagoz Cetinkaya Y, Arikan S, Unal S. In vitro activity of a new echinocandin, LY303366, compared with those amphotericin B and fluconazole against clinical yeast isolates. Antimicrob Agents Chemother 1997; 41: 1156-7.
19. Arikan S, Sancak B, Hascelik G. In vitro activity of caspungin compared to amphotericin B, fluconazole and itraconazole against Candida strains isolated in a Turkish University Hospital. Med Mycol 2005; 43: 171-8.
20. Rex J, Pfaller MA, Walsh TJ et al. Antifungal susceptibility testing: practical aspects and current challenges. Clin Microb Rev 2001; 14: 643-58.
21. Arthington-Skaggs BA, Warnock DW, Morrison CJ. Quantitation of Candida albicans ergosterol content improves the correlation between in vitro antifungal susceptibility test results and in vivo outcome after fluconazole treatment in a murine model of invaziv candidiasis. Antimicrob Agents Chemother 2000; 44: 2081-5.
22. Marr AK, Rustad TR, Rex JH, White TC. The trailing end point phenotype in antifungal susceptibility testing is pH dependent. Antimicrob Agents Chemother 1999; 43: 1383-6.
23. Espinel-Ingroff AV, Pfaller MA. Susceptibility test methods: yeast and filamentous fungi. In: Murray PR, Pfaller MA, Baron EJ, Jongensen JH, Yolken RH, (eds), Manual of Clinical Microbiology, 8th edn. Washington, DC: American Society for Microbiology, 2003: 1880-93.